KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Deferred Taxes: 2009-2025

Historic Deferred Taxes for Alnylam Pharmaceuticals (ALNY) over the last 3 years, with Sep 2025 value amounting to $5.6 million.

  • Alnylam Pharmaceuticals' Deferred Taxes rose 3534.36% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 816.33%. This contributed to the annual value of -$106.8 million for FY2024, which is 14873.63% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Deferred Taxes stood at $5.6 million for Q3 2025, which was down 42.50% from $9.7 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Deferred Taxes high stood at $9.7 million for Q2 2025, and its period low was -$107.4 million during Q4 2024.
  • Over the past 2 years, Alnylam Pharmaceuticals' median Deferred Taxes value was $454,000 (recorded in 2024), while the average stood at -$11.7 million.
  • Data for Alnylam Pharmaceuticals' Deferred Taxes shows a peak YoY skyrocketed of 3,534.36% (in 2025) over the last 5 years.
  • Over the past 2 years, Alnylam Pharmaceuticals' Deferred Taxes (Quarterly) stood at -$107.4 million in 2024, then surged by 3,534.36% to $5.6 million in 2025.
  • Its Deferred Taxes was $5.6 million in Q3 2025, compared to $9.7 million in Q2 2025 and $9.6 million in Q1 2025.